Pharmacotherapy of Schizophrenia

This presentation on pharmacotherapy of schizophrenia will review the role of shared decision-making, considerations in balancing efficacy and tolerability, the role of maintenance treatment, whether long-acting formulations help in reducing relapse risk, and when clozapine is indicated.
John M. Kane, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 5.96 MB
Released: December 8, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Intra-Cellular Therapies
Neurocrine Biosciences
Sage Therapeutics
Sunovion
Supernus Pharmaceuticals, Inc.

Related Content

Dr John M. Kane presents advances in treating tardive dyskinesia, from Clinical Care Options (CCO)

John M. Kane, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Physician Assistants: maximum of 1.0 hour of AAPA Category I CME credit Released: January 20, 2022 Expired: January 19, 2023

Dr John M. Kane presents an expert’s guide to tardive dyskinesia, from Clinical Care Options (CCO)

John M. Kane, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Physician Assistants: maximum of 0.75 hours of AAPA Category I CME credit Released: January 12, 2022 Expired: January 11, 2023

Dr. Greg Mattingly reviews recent advances in treating schizophrenia, from Clinical Care Options (CCO)

Greg Mattingly, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: maximum of 1.0 hour of AAPA Category I CME credit Social Workers: 1.0 ACE CE Credit Psychologists: 1.0 APA CE Credit Released: January 11, 2022 Expired: January 10, 2023

Sanjay Gupta, MD, on salient research studies of interest relevant to neuroscience, including agitation in dementia, insomnia, antipsychotics in schizophrenia, COVID-19, and provides clinical commentary from Clinical Care Options (CCO)

Sanjay Gupta, MD Released: December 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings